Keywords: Giant cell arteritis; Takayasu arteritis; Anti-TNF-α agents; Tocilizumab; Ustekinumab; Rituximab; Abatacept;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Inflammatory Bowel Diseases; Formalin-Fixed; Paraffin-Embedded; Next-Generation Sequencing; RNA-Seq; CD; Crohn disease; CDAI; Clinical Disease Activity Index; FFPE; formalin-fixed, paraffin-embedded; H&E; hematoxylin and eosin; I-Wk0; induction baseline;
Keywords: Interleukin-23 receptor; Monoclonal antibody; Ustekinumab; Interleukin-12/23p40; Th17; Pharmacodynamics;
Keywords: guttate psoriasis; HLA-C*06:02; psoriasis; ustekinumab; BSA; body surface area; HLA; human leukocyte antigen; IL; interleukin; PGA; physician global assessment; Th; T helper;
Keywords: Crohn's disease; Ulcerative colitis; Monoclonal antibody; Anti-TNF; Vedolizumab; Ustekinumab; Biologics;
Keywords: biologic; conventional systemic; malignancy; methotrexate; psoriasis; PSOLAR; tumor necrosis factor-α inhibitors; TNF-α inhibitors; ustekinumab; CI; confidence interval; NMSC; nonmelanoma skin cancer; OR; odds ratio; PSOLAR; Psoriasis Longitudinal Asses
Keywords: MTX; methotrexate; TNF; tumor necrosis factor; IL; interleukin; CTLA4; cytotoxic T-lymphocyte antigen 4; IFX; infliximab; ADA; adalimumab; GLM; golimumab; CZP; certolizumab pegol; ETN; etanercept; TCZ; tocilizumab; ABA; abatacept; RTX; rituximab; UTK; ust
Keywords: biological therapy; psoriasis; ustekinumab; ADA; antidrug antibodies; DLQI; Dermatology Life Quality Index; PASI; Psoriasis Area and Severity Index;
Keywords: Adalimumab; Infliximab; Etarnecept; Ustekinumab; Psoriasis; Drugs therapies; Polymorphisms; Effectiveness;
Keywords: Ustekinumab; Hepatopatía; Toxicidad farmacológicaUstekinumab; Liver disease; Drug toxicity
Keywords: acne inversa; adalimumab; anakinra; biologics; etanercept; hidradenitis suppurativa; infliximab; treatment; tumor necrosis factor–alfa; ustekinumab
Keywords: Terapia biológica; Reducción de dosis; Adalimumab; Etanercept; Infliximab; UstekinumabBiologic therapy; Dose reduction; Adalimumab; Etanercept; Infliximab; Ustekinumab
Keywords: Biologic therapy; Dose reduction; Adalimumab; Etanercept; Infliximab; UstekinumabTerapia biológica; Reducción de dosis; Adalimumab; Etanercept; Infliximab; Ustekinumab
Keywords: adalimumab; biologics; etanercept; infliximab; monitoring; psoriasis; psoriatic arthritis; safety; screening; ustekinumab; AAD; American Academy of Dermatology; ALP; alkaline phosphatase; ALT; alanine transaminase; ANA; antinuclear antibody; AST; aspartat
Keywords: Biologics; Dermatology; Etanercept; Adalimumab; Infliximab; Ustekinumab; Secukinumab; IVIG;
Keywords: Psoriasis; Clinical equivalence; Meta-analysis; Biologic agents; Infliximab; Ustekinumab; Adalimumab; EtanerceptPsoriasis; Equivalencia clínica; Metaanálisis; Biológicos; Infliximab; Ustekinumab; Adalimumab; Etanercept
Keywords: Adalimumab; Etanercept; Infliximab; Ustekinumab; Psoriasis; Escalation; Switching; Maintenance failureAdalimumab; Etanercept; Infliximab; Ustekinumab; Psoriasis; Intensificación; Cambio (switching); Fracaso secundario
Keywords: Adalimumab; Etanercept; Infliximab; Ustekinumab; Psoriasis; Intensificación; Cambio (switching); Fracaso secundarioAdalimumab; Etanercept; Infliximab; Ustekinumab; Psoriasis; Escalation; Switching; Maintenance failure
Keywords: ADA; adalimumab; CD; Crohn disease; CDAI; Crohn's Disease Activity Index; CrI; credible interval; CZP; certolizumab pegol; HR; hazard ratio; IBD; inflammatory bowel disease; IFX; infliximab; IL-12/23; interleukin 12/23; NAT; natalizumab; OR; odds ratio;
Primary biliary cholangitis: Old and novel therapy
Keywords: Primary biliary cholangitis; Primary biliary cirrhosis; Ursodeoxycholic acid; Obeticholic acid; Fibrates; Budesonide; Rituximab; Ustekinumab; Treatment;
Ustekinumab in the management of Crohn's disease: Expert opinion
Keywords: Anti-tumor necrosis factor agents; Crohn's disease; Monoclonal antibodies; Ustekinumab; Vedolizumab;
Actualisation 2018Â des recommandations de la Société française de rhumatologie (SFR) pour la prise en charge en pratique courante des malades atteints de spondyloarthrite
Keywords: Spondyloarthrite; Spondylarthrite ankylosante; Rhumatisme psoriasique; Traitement; Rééducation; Ãducation thérapeutique; AINS; Biomédicaments; Anti-TNF; Ustekinumab; Secukinumab; Chirurgie; Recommandations;
2018 update of French Society for Rheumatology (SFR) recommendations about the everyday management of patients with spondyloarthritis
Keywords: Spondyloarthritis; Ankylosing spondylitis; Psoriatic arthritis; Treatment; Rehabilitation; Therapeutic patient education; NSAIDs; Biologics; TNFα antagonists; Ustekinumab; Secukinumab; Surgery; Recommendations;
CARD14-associated papulosquamous eruption: A spectrum including features of psoriasis and pityriasis rubra pilaris
Keywords: CARD14; genetics; pityriasis rubra pilaris; psoriasis; treatment; ustekinumab; CAPE; CARD14-associated papulosquamous eruption; IL; interleukin; NF-κB; nuclear factor κ light-chain enhancer of activated B cells; PRP; pityriasis rubra pilari;
The spectrum of manifestations in desmoplakin gene (DSP) spectrin repeat 6 domain mutations: Immunophenotyping and response to ustekinumab
Keywords: Carvajal syndrome; EKC syndrome; ichthyosis; keratoderma; orphan disease; personalized medicine; pustular psoriasis; SAM syndrome; Th1; Th17; therapeutic repurposing; therapy; ustekinumab; woolly hair; CIE; congenital ichthyosiform erythroderma; DCWHKTA;
Secukinumab in psoriasis patients with prior ustekinumab treatment: Results of a single-center experience
Keywords: biologics; psoriasis; secukinumab; switch; ustekinumab;
Ustekinumab for Behçet's disease
Keywords: Ustekinumab; Behçet disease; Vasculitis; Oral ulcer; Biotherapy;
IL-23/Th17 targeted therapies in SAPHO syndrome. A case series
Keywords: SAPHO syndrome; IL-23; IL-17; Treatment; Ustekinumab; Secukinumab;
Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease
Keywords: Biologic; Inflammatory Bowel Disease; Therapeutic Drug Monitoring; UNITI; CD; Crohn's disease; CRP; C-reactive protein; FC; fecal calprotectin; HBI; Harvey Bradshaw Index; IBD; inflammatory bowel disease; IV; intravenous; Q4; every 4; Q8; every 8; SES-CD;
Nuevas dianas terapéuticas en la enfermedad inflamatoria intestinal
Keywords: Ustekinumab; Enfermedad inflamatoria intestinal; Enfermedad de Crohn; Colitis ulcerosa; Inhibidores de quinasa de Janus; Ustekinumab; Inflammatory bowel disease; Crohn's disease; Ulcerative colitis; Janus kinase (JAK) inhibitors;
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1Â year: Results from the CLEAR study
Keywords: psoriasis; secukinumab; ustekinumab; clinical trial; Psoriasis Area and Severity Index (PASI); efficacy; safety; AE; adverse event; DLQI; Dermatology Life Quality Index; EQ-5D-3L; EuroQoL 5-Dimension Health Questionnaire 3-level version; HAQ-DI; Health As
Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease
Keywords: Ustekinumab; Crohn's disease; Inflammatory bowel disease; Interleukin-12/23 monoclonal antibody; Interleukin-12; Interleukin-23;
Original articleBiologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population
Keywords: adalimumab; adherence; biologic; discontinuation; etanercept; infliximab; Medicare; psoriasis; specialty drug; ustekinumab;
Original articleComparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR])
Keywords: adalimumab; biologic; BSA; DLQI; effectiveness; efficacy; etanercept; infliximab; PGA; PSOLAR; Psoriasis Longitudinal Assessment and Registry; ustekinumab; %BSA; percentage of body surface area with psoriasis; CI; confidence interval; DLQI; Dermatology Li
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
Keywords: clear or almost clear skin; clinical trial; head to head; plaque psoriasis; secukinumab; superiority; ustekinumab; 90% or more improvement in baseline Psoriasis Area and Severity Index; AE; adverse event; DLQI; Dermatology Life Quality Index; HRQoL; healt
Ustekinumab in adolescent patients age 12 to 17Â years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study
Keywords: adolescent; biologic; children; pediatric; psoriasis; systemic therapy; ustekinumab; AE; adverse event; CDLQI; Children's Dermatology Life Quality Index; HRQoL; health-related quality of life; HSD; half-standard dose; PASI; Psoriasis Area and Severity Ind
Targeting the IL-17/IFN-γ axis as a potential new clinical therapy for type 1 diabetes
Keywords: Ustekinumab;; Stelara;; Type 1 diabetes;; IL-17;; IFN-γ;; Clinical trial
Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease-The McGill experience
Keywords: Crohn's disease; Ustekinumab; TNF-alpha inhibitors; Biologics;
Treatment of spondyloarthritis beyond TNF-alpha blockade
Keywords: Spondyloarthritis; Psoriatic arthritis; Axial spondyloarthritis; Ankylosing spondylitis; Anti-TNF failure; Ustekinumab; Anti-interleukin-17 agents; Apremilast
Update on Ustekinumab for the Treatment of Crohn's Disease
Keywords: Ustekinumab; Interleukin-12; Interleukin-23; Crohn's disease; Psoriasis; Interleukin-12/23 monoclonal antibody;
The interplay between regulatory and effector T cells in autoimmune hepatitis: Implications for innovative treatment strategies
Keywords: Autoimmunity; Tolerance; Regulatory; Th17 Cells; Ustekinumab; Tocilizumab;
Spanish Evidence-Based Guidelines on the Treatment of Psoriasis With Biologic Agents, 2013. Part 1: On Efficacy and Choice of Treatment
Keywords: Psoriasis; Biologic agents; Clinical practice guidelines; Treatment; Adalimumab; Etanercept; Infliximab; Ustekinumab; Biologic therapy
Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis con agentes biológicos, 2013. I. Consideraciones de eficacia y selección del tratamiento
Keywords: Psoriasis; Biológicos; Guía; Tratamiento; Adalimumab; Etanercept; Infliximab; Ustekinumab; Terapia biológica
Ustekinumab associated thrombotic thrombocytopenic purpura
Keywords: TTP/HUS; Plasmapheresis; Ustekinumab; Thrombotic thrombocytopenic purpura
Concomitant occurrence of acneiform eruption, alopecia areata, and urticaria during adalimumab treatment in a patient with pustulosis palmoplantaris: Case report and literature review
Keywords: acne; adalimumab; alopecia areata; urticaria; ustekinumab
Ustekinumab en paciente con enfermedad de Crohn y psoriasis inducida por anti-TNF-α
Keywords: Enfermedad de Crohn; Psoriasis; Anti-TNF-α; UstekinumabCrohn's disease; Psoriasis; Anti-TNF-α; Ustekinumab
Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)
Keywords: Ustekinumab; Psoriasis; Taiwan; Korea; Interleukin-12/23 monoclonal antibody
Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: Rationale for dosing recommendations
Keywords: psoriasis; Psoriasis Area and Severity Index; serum concentration; ustekinumab; weight-based doseLLOQ, lower limit of quantification; PASI, Psoriasis Area and Severity Index; PASI 75, at least 75% improvement from baseline score in Psoriasis Area and Seve